Pfiz­er, Mer­ck KGaA re­port their lat­est set­back with check­point con­tender Baven­cio

Mer­ck KGaA and their part­ners at Pfiz­er have an­oth­er big set­back to re­port for their PD-L1 check­point drug Baven­cio.

The check­point ei­ther alone or in com­bi­na­tion with chemother­a­py failed to hit ei­ther the over­all sur­vival or pro­gres­sion-free sur­vival end­points in their Phase III JAVELIN Ovar­i­an 200 study for drug-re­sis­tant ovar­i­an can­cer. The news comes 9 months af­ter re­searchers al­so re­port­ed a fail for their check­point on sec­ond-line lung can­cer, lead­ing some an­a­lysts to con­clude that their big Baven­cio pro­gram was look­ing like a run­ner-up in the in­tense­ly com­pet­i­tive field.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER